Separately, Citigroup boosted their price objective on Cellectis from $34.00 to $36.00 in a research report on Thursday, August 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Cellectis has a consensus rating of “Hold” and a consensus price target of $15.17.
Cellectis Stock Down 2.7 %
Shares of NASDAQ CLLS opened at $2.19 on Thursday. The business has a 50-day moving average of $2.55 and a 200-day moving average of $2.94. The firm has a market capitalization of $99.79 million, a price-to-earnings ratio of -0.95 and a beta of 2.01. Cellectis has a 12 month low of $2.00 and a 12 month high of $9.81. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.10.
Hedge Funds Weigh In On Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- International Game Technology is Well Worth the Gamble
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.